GlassScriptPhysician profile
Dharti Panara
NPI 1417309881
$1,279.37
in general payments reported to CMS, 2019-2025
30 companies · $448 in 2025
The $448 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66.07 · 2020: $98.60 · 2022: $152 · 2023: $369 · 2024: $146 · 2025: $448.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $963.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $962.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $172.00 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $102.02 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $98.45 | 2020-2024 | Mounjaro, Amyvid, Zepbound |
| Abbvie INC. | $80.13 | 2022-2025 | |
| Ucb, INC. | $79.36 | 2023-2025 | Briviact, Nayzilam |
| Exact Sciences Corporation | $76.48 | 2023-2025 | Cologuard Collection Kit |
| Lundbeck LLC | $68.90 | 2023-2025 | Vyepti, Rexulti |
| Amgen INC. | $68.51 | 2019-2022 | |
| Daiichi Sankyo INC. | $61.94 | 2019-2023 | Injectafer |
| Argenx US, INC. | $51.67 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Vanda Pharmaceuticals INC. | $51.08 | 2025 | Ponvory |
| Pfizer INC. | $47.42 | 2020-2025 | |
| Glaxosmithkline, LLC. | $29.22 | 2022 | |
| Biogen, INC. | $27.40 | 2023 | Tysabri, Vumerity, Avonex |
| Springworks Therapeutics, INC. | $20.41 | 2025 | Gomekli |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $20.06 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $20.00 | 2022 | |
| Neurelis, INC. | $18.84 | 2023 | Valtoco |
| Eisai INC. | $18.29 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.13 | 2025 | |
| Axsome Therapeutics, INC. | $17.15 | 2023 | Sunosi |
| Xeris Pharmaceuticals, INC. | $17.01 | 2023 | Gvoke Hypopen |
| Impel Pharmaceuticals INC. | $16.55 | 2023 | Trudhesa |
| Alexion Pharmaceuticals, INC. | $16.31 | 2024 | Ultomiris |
| Otter Pharmaceuticals, LLC | $15.15 | 2025 | Sympazan |
| Endo Pharmaceuticals INC. | $14.45 | 2020 | |
| Mdd US Operations, LLC | $14.40 | 2023 | Xadago, Apokyn |
| Acorda Therapeutics, INC | $13.79 | 2023 | Inbrija |
| Regeneron Healthcare Solutions, INC. | $12.14 | 2019 | |
| Aucta Pharmaceuticals, INC. | $12.11 | 2024 | Motpoly Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dharti Panara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.